Immunome, Inc. (NASDAQ:IMNM) Receives $29.80 Average PT from Analysts

Immunome, Inc. (NASDAQ:IMNM) has earned an average recommendation of “Buy” from the six research firms that are presently covering the firm, MarketBeat.com reports. Six research analysts have rated the stock with a buy rating. The average 12-month price objective among brokers that have covered the stock in the last year is $29.80.

A number of analysts recently commented on IMNM shares. Guggenheim started coverage on shares of Immunome in a report on Monday, April 15th. They issued a “buy” rating and a $35.00 target price on the stock. JPMorgan Chase & Co. started coverage on shares of Immunome in a report on Tuesday, April 30th. They issued an “overweight” rating and a $24.00 target price on the stock. Wedbush reiterated an “outperform” rating and issued a $33.00 target price on shares of Immunome in a report on Thursday. Finally, Piper Sandler started coverage on shares of Immunome in a report on Friday, May 31st. They issued an “overweight” rating and a $27.00 target price on the stock.

Insider Activity

In other news, Director Jean Jacques Bienaime purchased 2,000 shares of the business’s stock in a transaction dated Tuesday, May 21st. The shares were acquired at an average price of $13.57 per share, for a total transaction of $27,140.00. Following the completion of the acquisition, the director now directly owns 9,615 shares of the company’s stock, valued at $130,475.55. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 8.60% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in IMNM. Cerity Partners LLC purchased a new position in Immunome during the fourth quarter valued at approximately $656,000. Emfo LLC purchased a new position in Immunome during the fourth quarter valued at approximately $633,000. Jump Financial LLC purchased a new position in Immunome during the fourth quarter valued at approximately $172,000. Mayo Clinic purchased a new position in Immunome during the fourth quarter valued at approximately $1,161,000. Finally, Avidity Partners Management LP purchased a new position in Immunome during the fourth quarter valued at approximately $14,268,000. 44.58% of the stock is owned by hedge funds and other institutional investors.

Immunome Trading Up 3.0 %

IMNM stock opened at $16.51 on Wednesday. Immunome has a 52 week low of $6.13 and a 52 week high of $30.96. The company has a market capitalization of $990.10 million, a price-to-earnings ratio of -2.19 and a beta of 1.79. The firm’s 50-day moving average is $13.81 and its two-hundred day moving average is $17.62.

Immunome (NASDAQ:IMNM) last released its earnings results on Tuesday, May 14th. The company reported ($0.34) EPS for the quarter, topping analysts’ consensus estimates of ($0.80) by $0.46. Immunome had a negative net margin of 1,829.44% and a negative return on equity of 37.33%. The business had revenue of $1.03 million for the quarter, compared to the consensus estimate of $4.00 million. On average, equities research analysts predict that Immunome will post -1.45 earnings per share for the current year.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.